Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Despina Fotiou

Showing results (71-80 of 108) with videos related to

Pageof 11
Sort By:
Journal of Bone Oncology|November 11, 2025
Bone disease burden does not impact overall survival in newly diagnosed patients with multiple myeloma - a single center, retrospective imaging analysis on 119 patientsEvangelos Terpos, Vassilis Koutoulidis, Ioannis Ntanasis-Stathopoulos, et al.
Blood Cancer Journal|February 27, 2023
Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathyMaria Moscvin, Christine Ivy Liacos, Tianzeng Chen, et al.
Haematologica|February 15, 2024
Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I/II studyEvangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, et al.
Blood Cancer Journal|August 3, 2021
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatmentEvangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 23, 2025
Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring DialysisDespina Fotiou, Foteini Theodorakakou, Eirini Solia, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 15, 2024
Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in GreeceEfstathios Kastritis, Ioannis Ntanasis-Stathopoulos, Foteini Theodorakakou, et al.
Hemasphere|August 5, 2022
Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA TherapyIoannis Ntanasis-Stathopoulos, Vangelis Karalis, Maria Gavriatopoulou, et al.
Blood Advances|January 4, 2018
Cardiac and renal complications of carfilzomib in patients with multiple myelomaMeletios A Dimopoulos, Maria Roussou, Maria Gavriatopoulou, et al.
American Journal of Hematology|July 19, 2025
Determinants of 15-Year Progression-Free Survival in Multiple Myeloma; Real-World Data From a Single InstitutionMeletios A Dimopoulos, Ioannis Ntanasis-Stathopoulos, Despina Fotiou, et al.
British Journal of Haematology|January 22, 2026
Clinical outcomes in newly diagnosed patients with Waldenström's macroglobulinaemia treated in a tertiary academic centreMaria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, et al.
Pageof 11

Showing results (71-80 of 108) with videos related to

Sort By:
Pageof 11
Journal of Bone Oncology|November 11, 2025
Bone disease burden does not impact overall survival in newly diagnosed patients with multiple myeloma - a single center, retrospective imaging analysis on 119 patientsEvangelos Terpos, Vassilis Koutoulidis, Ioannis Ntanasis-Stathopoulos, et al.
Blood Cancer Journal|February 27, 2023
Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathyMaria Moscvin, Christine Ivy Liacos, Tianzeng Chen, et al.
Haematologica|February 15, 2024
Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I/II studyEvangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, et al.
Blood Cancer Journal|August 3, 2021
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatmentEvangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 23, 2025
Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring DialysisDespina Fotiou, Foteini Theodorakakou, Eirini Solia, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 15, 2024
Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in GreeceEfstathios Kastritis, Ioannis Ntanasis-Stathopoulos, Foteini Theodorakakou, et al.
Hemasphere|August 5, 2022
Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA TherapyIoannis Ntanasis-Stathopoulos, Vangelis Karalis, Maria Gavriatopoulou, et al.
Blood Advances|January 4, 2018
Cardiac and renal complications of carfilzomib in patients with multiple myelomaMeletios A Dimopoulos, Maria Roussou, Maria Gavriatopoulou, et al.
American Journal of Hematology|July 19, 2025
Determinants of 15-Year Progression-Free Survival in Multiple Myeloma; Real-World Data From a Single InstitutionMeletios A Dimopoulos, Ioannis Ntanasis-Stathopoulos, Despina Fotiou, et al.
British Journal of Haematology|January 22, 2026
Clinical outcomes in newly diagnosed patients with Waldenström's macroglobulinaemia treated in a tertiary academic centreMaria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, et al.
Pageof 11